• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transcarent Completes Merger With Accolade

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans

    Serving 20 Million Members & 1,700 Employer and Health Plan Clients

    Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/

    With the completion of the transaction, Transcarent will offer a health and care experience that is unmatched in its ability to offer choice, quality, and affordability to health consumers, self-insured employers, and health plans. Transcarent's AI-powered WayFinding and comprehensive Care Experiences – Cancer Care, Surgery Care, Weight Health – along with its Pharmacy Benefit offering combined with Accolade's leadership in health advocacy, expert medical opinion, and virtual primary care, offers a broad array of choices to make it easy for people to get the services they need, deliver better health outcomes, and significantly reduce costs.

    "Transcarent and Accolade coming together is an important step to make it easier for everyone to access the high-quality, affordable health and care they deserve," said Glen Tullman, Chief Executive Officer of Transcarent. "WayFinding is already delivering faster and more personalized answers to critical health questions and easy access to care, when and where people need it, and always on their terms. Whether that's meeting virtually with their trusted primary care physician, instant connection to a Care Advocate, or getting care for complex needs like cancer treatment or surgery. Adding Accolade's people and capabilities will significantly enhance our existing offerings. We're creating an entirely new way to experience health and care. We are truly better together."

    We Deliver the Most Comprehensive, Personalized Health and Care Experience

    It's Only Getting Better

    Together, Transcarent and Accolade are making it easy to get expert clinical guidance and high-quality care on a single, trusted platform. The experience will be enhanced by better technology, better care, and better access all in one place:

    • Investing in Technology to Deliver Better Access and Answers

      Transcarent and Accolade have independently invested in AI and technology systems that make their experiences easier to use, resulting in industry leading engagement that delivers better health outcomes and drives down costs. The expansive data-driven platform brings together Transcarent's AI-powered WayFinding with Accolade's True Health Actions, delivering clinical guidance personalized for each Member.



      WayFinding is the first experience using generative AI application to ensure people can both understand and use their health and care benefits. By combining benefits navigation and clinical guidance with instant access to care providers, WayFinding supports each person throughout their health and care journey.



      True Health Actions, developed by Accolade, begin by ingesting employer and health plan data, Electronic Medical Record data, and various other data sets to create an individual Member profile that includes clinical and social factors. Members are then given a True Health Action Plan. True Health Action plans are used to inform targeted outreach for case management, to create care suggestions, and to support collaboration with Care Advocates and Health Guides.



      Generative AI solutions, pioneered by software engineers at Transcarent and Accolade, are being used to enable doctors, nurses, and specialists to be more productive, so they have the time to focus on their patients instead of cumbersome and time-consuming administrative work, eliminating much of the administrative, billing, and prescription work they used to do.
    • More Care Delivered the Way You Want It

      Health consumers can get the care they need, on their terms. Whether someone wants to call us, get Care in 60 Seconds, schedule an appointment, or talk to our AI Care Assistant, care is always available, 24x7x365. Transcarent is their one place to go for health needs, simple or complex: get primary and urgent care, schedule an appointment for recurring chronic conditions with your regular doctors (virtual or in their office) or manage complex care like cancer or surgery. Members receive personalized guidance, exceptional care, and an easy to understand Health Action Plan to optimize health outcomes.



      We have a shared commitment to delivering a quality-first experience. Whether leaning on strengths in advocacy, expert medical opinions, and primary care, through a Transcarent Care Experience, or providing easy access to one of our Trusted Partners, Members have better health outcomes and those paying for care see lower costs.



      We also believe that trust is paramount, and it comes from aligning on the principle that the best care delivered may be reducing unnecessary treatments, procedures, and surgeries by ensuring quality information and clinical consultations are available early in the care process. Through access to industry-leading expert medical opinions from industry partners and our own 2nd.MD offering, Members have access to expert physician specialists representing all specialties and subspecialties.
    • More Choice in Point Solutions and Care Experiences

      Accolade's Trusted Partner Ecosystem of point solutions and Transcarent's relationships including local and virtual providers, will now be offered together in our Experience Store, allowing employers and health plans to choose what's best for the people they serve --- all available on one secure platform --- and accessible through single sign-on integration. Deep integration with point solution partners in areas like mental health, diabetes, fertility and musculoskeletal care will allow our platform to meet the diverse care needs of the populations we serve while reducing fragmentation and increasing appropriate utilization.

    "Together we will now have the largest Experience Store with solutions covering a broad range of health conditions. This merger provides health consumers, employers, and health plans with more options to meet each of their diverse health and care needs. Powered by technology that drives personalized solutions, higher engagement, and easy access to physicians and other healthcare professionals when needed, we offer choice and put people back in charge of their care, which delivers measurably better health and care outcomes and does so at lower overall costs. This is far beyond legacy navigation," said Snezana Mahon, Pharm.D., President of Transcarent.

    Leadership Team

    Glen Tullman will continue as Chief Executive Officer of the combined organization. The company is also excited to announce the promotion of Snezana Mahon, Pharm.D., to President. The go-forward leadership team will focus on delivering the same exceptional service and support that both organizations have delivered independently while introducing new capabilities that enhance the overall health and care experience of our Members.

    The Executive Leadership Team, reporting to Tullman, includes key business talent from both organizations:

    • Stephanie Peng, Chief Financial Officer
    • Kristen Bruzek, EVP, Care Delivery Operations
    • Connie Hwang, MD, Chief Clinical Officer
    • Laurie McGraw, Chief Commercial Officer
    • Abhi Pathak, Chief Product Officer
    • Drew Garner, Co-Chief Technology Officer
    • Praful Kaul, Co-Chief Technology Officer
    • Caitlin Fleming, Chief Strategy Officer
    • Janine Gianfredi, Chief Marketing Officer
    • Tom Richards, EVP, Consultant Relations & Business Development
    • Erica Davila, General Counsel
    • Rachel Stillman, Chief of Staff

    Transaction Details

    Transcarent announced the intent to acquire Accolade (NASDAQ:ACCD) on January 8th, completing the transaction in three months.

    Under the terms of the agreement, Accolade shareholders received $7.03 per share in cash. The acquisition financing was led by General Catalyst and Glen Tullman's 62 Ventures, along with existing and new investors, in addition to cash on hand from the combined company's balance sheet and debt financing led by J.P. Morgan.

    The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq.

    For more information on this announcement, please visit: www.transcarent.com/transcarent-accolade-one-place

    About Transcarent

    Transcarent and Accolade have come together to create the One Place for Health and Care, the leading personalized health and care experience that delivers unmatched choice, quality, and outcomes. Transcarent's AI-powered WayFinding, comprehensive Care Experiences – Cancer Care, Surgery Care, Weight Health – and Pharmacy Benefits offerings combined with Accolade's health advocacy, expert medical opinion, and primary care, allows us to meet people wherever they are on their health and care journey. Together, more than 20 million people have access to the combined company's offerings. Employers, health plans, and leading point solutions rely on us to provide trusted information, increase access, and deliver care.

    For more information, visit www.transcarent.com or www.accolade.com, and follow us on LinkedIn, X, Instagram, and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250407811112/en/

    Media Contact:

    Transcarent

    Leslie Krigstein, VP, Communications & Government Affairs

    [email protected]

    802-598-3305

    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary